The year's new drugs and biologics 2020
| Autor: | Ann I. Graul, Lisa Ann Sorbera |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Premature aging
Allergen immunotherapy Pediatrics medicine.medical_specialty Biological Products Ebola virus business.industry SARS-CoV-2 Outbreak Disease medicine.disease_cause medicine.disease Hepatitis D COVID-19 Drug Treatment Orphan drug Pharmaceutical Preparations Pandemic Medicine Humans business Drug Approval |
| Zdroj: | Drugs of today (Barcelona, Spain : 1998). 57(2) |
| ISSN: | 1699-3993 |
| Popis: | 2020 will go down in history as a year marked in every respect by the emergence and astonishingly rapid spread of the first major global viral pandemic in a century. It seems like nearly every event or story of the year was influenced in some way by COVID-19, and in that respect, the year ended on a high note with the authorization for emergency use of the first vaccines to prevent SARS-CoV-2 infection and drugs to treat COVID-19. Despite the pandemic's dominance of the 2020 headlines, productivity was at a record high level across all therapeutic areas, as seen by the number of products in this year's review: approximately 50% more than the previous year. Notable achievements include the launch of the first treatment for hepatitis D; regulatory decisions on a suite of biologics for the prevention and treatment of Ebola virus disease, fruit of the 2016-2018 outbreak in the Democratic Republic of Congo; the approval of the first-ever drug to treat Hutchinson-Gilford progeria syndrome, a rare genetic disorder that leads to premature aging; the first treatment developed specifically for thyroid eye disease, also known as Graves' ophthalmopathy; the first nonhormonal, on-demand, vaginal pH-regulating contraceptive; and the first oral allergen immunotherapy for peanut allergy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|